US Stock MarketDetailed Quotes
DXCM DexCom
- 124.340
- -13.670-9.91%
Close Apr 26 16:00 ET
- 124.380
- +0.040+0.03%
Post 19:54 ET
49.45BMarket Cap80.74P/E (TTM)
138.805High124.080Low8.58MVolume132.500Open138.010Pre Close1.10BTurnover2.20%Turnover Ratio95.65P/E (Static)397.68MShares142.00052wk High22.01P/B48.52BFloat Cap74.75052wk Low--Dividend TTM390.22MShs Float164.863Historical High--Div YieldTTM10.67%Amplitude0.340Historical Low127.944Avg Price1Lot Size
DexCom Stock Forum
Sign in to post a comment
The Market is No Longer Rational - Here are Tomorrow's Top 4 Picks (plus 2 bonus picks)
$Microsoft(MSFT.US$ - They make money and do AI things so it will drop -20%
- Bull Case - They lose a lot of money
- Bear Case - They make a lot of money and they're involved in AI
$Alphabet-A(GOOGL.US$ (forgot) - They make money and AI so it will drop -18.75%
- Bull Case - They lose money and search market share shrinks heavily. They have Googler's streak through Pinchia's office for a group sit-in regarding go...
- Bull Case - They lose a lot of money
- Bear Case - They make a lot of money and they're involved in AI
$Alphabet-A(GOOGL.US$ (forgot) - They make money and AI so it will drop -18.75%
- Bull Case - They lose money and search market share shrinks heavily. They have Googler's streak through Pinchia's office for a group sit-in regarding go...
15
5
Cybersecurity and Dialysis Stocks Soar, Lithium Sinks
After-hours Stock Action
CrowdStrike ( $CrowdStrike(CRWD.US$ ): Cybersecurity Juggernaut
- Post-Earnings Surge: Up over 20% after beating estimates and strong guidance.
- Stellar Performance: Stock up over 130% in the past year, outperforming First Trust Cybersecurity ETF ( $First Trust Exch Traded Fund 2 Nasdaq Cybersecurity Etf(CIBR.US$ ).
Paccar ( $PACCAR Inc(PCAR.US$ ): Record High on Price Target Hike
JPMorgan Boost: Reiterated overwei...
CrowdStrike ( $CrowdStrike(CRWD.US$ ): Cybersecurity Juggernaut
- Post-Earnings Surge: Up over 20% after beating estimates and strong guidance.
- Stellar Performance: Stock up over 130% in the past year, outperforming First Trust Cybersecurity ETF ( $First Trust Exch Traded Fund 2 Nasdaq Cybersecurity Etf(CIBR.US$ ).
Paccar ( $PACCAR Inc(PCAR.US$ ): Record High on Price Target Hike
JPMorgan Boost: Reiterated overwei...
DexCom's start of profitability could signal fast earnings growth, justifying strong share price gains. Despite recent slowdown, the company might continue to execute with prowess.
DexCom's recent profitability and reinvestment are positive signs. The stock's 225% return over five years indicates investors recognize these changes. If maintained, DexCom could have a promising future.
DexCom's high P/S ratio is justified by its superior revenue growth and future prospects. Investors' confidence in the company's future revenues is reflected in this ratio, suggesting the share price won't fall significantly soon.
Despite DexCom's higher-than-average return on equity, the company's high debt levels could pose a significant risk. While debt can boost return on equity, it is only justifiable when a company can generate substantial returns from it.
Baird analysts anticipate Insulet's earnings to grow faster than their annual sales of approx. 20%. DexCom's margins predicted to expand with sales growth over 20% annually before GLP-1s impact. Boston Scientific considered a top-level medtech enterprise by Baird's Rescott.
Three things to watch this week: inflation, OPEC+reaction and insulin stocks
Inflation data is on watch and expected to fall in Australia and the US. But expect smart money to flow into healthcare stocks as job growth is slowing and surplus income is falling. We cover healthcare stocks to maybe jab into your portfolio. Plus, the potential OPEC+ meeting outcomes with stocks to watch given the oil price is in 'oversold' territory'
1- US inflation to fall under the Fed's target. Wow. Australia's inf...
1- US inflation to fall under the Fed's target. Wow. Australia's inf...
22
ColumnsMedical-device Stock Selloff Caused by Ozempic Fears Has Gone Too Far—Now They're Rebounding
A new generation of highly effective weight-loss and diabetes drugs known as GLP-1s has led Wall Street to spell doom for companies that have profited from obesity problem. However, the reaction on Wall Street has been extreme, creating opportunities for cooler heads, some analysts and investors say.
To be sure, drugs such as $Novo-Nordisk A/S(NVO.US$'s Ozempic and Wegovy, and Eli Lilly's Mounjaro have p...
To be sure, drugs such as $Novo-Nordisk A/S(NVO.US$'s Ozempic and Wegovy, and Eli Lilly's Mounjaro have p...
10
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
100k : Will TEAM report earnings pre or post market
Foodie Investor : Hilarious and spot on prediction
gabrielgoh : Hahahaahahahahhaa this is actually funny
Money Thrill : It's really Turki
ThirtyOne : Beautiful analysis!